EANO 2010 Final Programme.pdf - Vienna Medical Academy

medacad

EANO 2010 Final Programme.pdf - Vienna Medical Academy

The EUROPEAN

ASSOCIATION of

NEUROONCOLOGY

9 th MEETING

2010

September 16-19

MAASTRICHT

MAASTRICHT EXHIBITION & CONGRESS CENTRE (MECC)

FINAL PROGRAMME www.eano.eu


Currently Recruiting

CilENgitide in combination with Temozolomide and Radiotherapy In newly

diagnosed glioblastoma phase III randomized Clinical trial

A randomized multicenter, open-label, controlled phase III study to evaluate cilengitide in combination

with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide

maintenance therapy) versus standard therapy alone in newly diagnosed glioblastoma patients with

methylated MGMT gene promoter status.

Primary Endpoint: Overall Survival Time

Cilengitide (EMD 121974) currently is under clinical investigation and has not been approved for use in the United States, Canada, Europe, or elsewhere. The

product has not been proved to be safe or effective and any claims of safety and effectiveness can be made only after regulatory review of the data and

approval of the labeled claims.

The CENTRIC study is conducted in partnership with the European Organisation for Research and Treatment of Cancer (EORTC) and in collaboration with the

Canadian Brain Tumour Consortium (CBTC).

Please refer to www.clinicaltrials.gov for further information.

Currently Recruiting

Cilengitide in subjects with newly diagnOsed glioblastoma multifoRme and

unmethylated MGMT genE promoter

A randomized multicenter, open-label phase II study, investigating two cilengitide regimens in combination with

standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance

therapy) versus standard therapy alone in newly diagnosed glioblastoma patients with unmethylated MGMT

gene promotor status.

Primary Endpoint: Overall Survival Time

Cilengitide (EMD 121974) currently is under clinical investigation and has not been approved for use in the United States, Canada, Europe, or elsewhere. The

product has not been proved to be safe or effective and any claims of safety and effectiveness can be made only after regulatory review of the data and

approval of the labeled claims.

The CORE study is in collaboration with the Canadian Brain Tumour Consortium (CBTC).

Please refer to www.clinicaltrials.gov for further information.

Merck Serono Oncology | Combination is key


TABLE OF CONTENTS

General

Committees, Board and Organisation ..................................................................2

Welcoming Address ..........................................................................................3

Floorplan of the MECC .......................................................................................4

Overview Maastricht & Map................................................................................6

Acknowledgements – EANO 2012 – CME Credits ...................................................7

Programme at a Glance.....................................................................................8

Scientific Programme

- Thursday, September 16, 2010 (Educational Day) ..............................................9

- Friday, September 17, 2010 ..........................................................................11

Nurses Session ..................................................................................16

- Saturday, September 18, 2010 ......................................................................17

- Sunday, September 19, 2010.........................................................................22

Meetings .......................................................................................................23

Corporate Satellite Meetings.............................................................................23

Poster Topics .................................................................................................24

Scientific Information ......................................................................................25

General Information

Social Events (Welcome Reception, EANO Party) .................................................27

General Information........................................................................................28

Registration Fees ............................................................................................32

Exhibition

Exhibitors Standing.........................................................................................34

Exhibitors Listing ............................................................................................35

Map Public Transportation Maastricht.................................................................36

Printed in Austria by: ROBIDRUCK, 1200 Vienna – www.robidruck.co.at

www.eano.eu 1

E A N O 2 0 1 0


COMMITTEES – BOARD – ORGANISATION

COMMITTEES – BOARD - ORGANISATION

EANO IX Organising Committee

Albert Twijnstra, Congress President

Brigitta Baumert, Scientific Secretary

Clemens Dirven

Linda Jacobi

Pieter Leffers

Hilly Tjon-a-Fat

Winetta vd Graaf

Pieter Wesseling

EANO Secretariat

Mrs. Philomène Klomp

P.O. Box 219

NL-5170 AE Kaatsheuvel

The Netherlands

T: +31 416 54 00 37

F: +31 848398070

office@eano.eu

www.eano.eu

Exhibition and Advertisements

Medizinische Ausstellungs- und

Werbegesellschaft (MAW)

Mrs. Andrea Etz

Freyung 6

A-1010 Vienna, Austria

T: +43 1 536 63 - 42

F: +43 1 535 60 16

maw@media.co.at

EANO Board

Robin Grant, President (UK)

Francesc Graus, Vice President (E)

Clemens Dirven, Treasurer (NL)

Bettina Müller, Secretary (D)

Lorenzo Bello, Board Member (I)

Wolfgang Grisold, Board Member (A)

Beatrice Melin, Board Member (S)

Shanne McNamara, Nurse Member (UK)

Susan Short, Board Member (UK)

Riccardo Soffietti, Board Member (I)

Wolfgang Wick, Board Member (D)

Khe Hoang Xuan, Board Member (F)

Conference Organisation,

Abstract Management,

Sponsoring

EANO 2010 Secretariat

Vienna Medical Academy (VMA)

Mrs. Romana Koenig,

Mrs. Alissa McGregor

Alser Strasse 4, A-1090 Vienna, Austria

T: +43 1 405 13 83 0

F: +43 1 407 82 74

eano2010@medacad.org

www.medacad.org

Hotel Accommodation

Reservations Office Maastricht Booking

Service

MECC Maastricht

Mrs. Diane Krutzen

T: +31 (0)43 38 38 359

F: +31 (0)43 38 38 309

mbs@mecc.nl

www.maastrichtbookingservice.nl

2 www.eano.eu


WELCOMING ADDRESS

Dear colleagues and friends,

It is our great pleasure to welcome you to the 9 th EANO Conference in Maastricht,

the Netherlands, from 16 th - 19 th September 2010.

The local organizing committee provided us, along with EANO, with an interesting

postgraduate course on Thursday 16 th of September and an attractive scientific

program with key topics in the field of NeuroOncology organized in a multidisciplinary

spirit.

The Scientific program will cover the most important topics of our field in main

symposia, Meet-the-Expert sessions and Keynote lectures. As usual the

interdisciplinary spirit will be the basis of the Congress. Colleagues from all the

Neuro-Oncological disciplines and nurses are participating actively at the oral and

poster presentations.

The sessions will take place in the Maastricht Exhibition and Congress Centre

(MECC), a modern conference venue centrally situated in Maastricht, with

facilities for international conventions hosting over 2,000 delegates.

Maastricht is located in the most southern part of the Netherlands, where Romans

forded the river Meuse. Since then, Maastricht has been at the crossroads of

cultures and trade. Cobbled streets, boutiques and castles give the city its special

character. The many shops, pubs, excellent restaurants, terraces, churches,

museums and the gastronomic lifestyle of the inhabitants make Maastricht a

great place to be.

We all hope that you will have a truly enjoyable, and excellent conference in

Maastricht.

We look forward to welcoming you in Maastricht.

Albert Twijnstra Robin Grant

President, Organising Committee President, EANO

Brigitta Baumert

Scientific Secretary, Organising Committee

Congress Venue EANO IX

Maastricht Exhibition & Congress Centre (MECC)

Forum 100

6229 GV Maastricht, The Netherlands

T: +31 43 3838601 (EANO registration desk at MECC,

during registration hours only)

F: +31 43 3838300 – Please send to the attention of EANO 2010

(www.mecc.nl)

www.eano.eu 3

WELCOMING ADDRESS


F L O O R P L A N

F L O O R P L A N

Maastricht Exhibition & Congress Centre (MECC)

FLOORPLAN LEVEL 1 (entrance level)

Lecture Rooms:

Auditorium 1

Auditorium 2

Preview Room:

Office room 1.3

EANO 2010 Registration Desk

& CME Credits Counter

Scientific Posters

Exhibition

Coffee/Lunch Area

Internet stations

(sponsored by F. Hoffmann-

La Roche Ltd.)

WLAN within registration area

EANO Association Booth

Information Table

Message Board

Access to level 0

Forum Passage

Promenade

2.1-2.14

Void

4 www.eano.eu

Lobby

0 level

2625+P

Access to level 0

5100+P

EANO 2010 Registration desk

Void

Lobby

0level

Pantry

E.E.

L

T

Pantry

2975+P

1.3

Storage

Folding wall

4200+P

Lobby

0level

1.2

Terrace

Preview

(for speakers only)

Folding wall

Expo Foyer

Entrance

Office DM

MECC Cafe:

Internet stations

(sponsored by

F. Hoffmann-

La Roche Ltd.)


F L O O R P L A N

Maastricht Exhibition & Congress Centre (MECC)

FLOORPLAN LEVEL 0 (lower level)

TC

TC

TC

1 2 3

N.U.

N.U.

K

K

0.3

Copenhagen

4

5

14

16

11

11

Access

to level 1

5

K

K

K

Trajectum

Cloak room

0.4

Brussels

0.5

Paris

www.eano.eu 5

K

6

6

L

Lecture Rooms:

Room Brussels

Room Paris

Lecture/Meeting Room:

Room Copenhagen

Scientific Posters/

Coffee/Lunch Area

Cloak room

Access to level 1

F L O O R P L A N


OVERVIEW MAASTRICHT & MAP

OVERVIEW MAASTRICHT & MAP

6 www.eano.eu


ACKNOWLEDGEMENTS

The European Association of NeuroOncology gratefully acknowledges the

support of the following institutions, companies and organisations (list correct as

per date of printing):

Platinum Sponsor:

Gold Sponsors:

Silver Sponsor:

Others:

Future EANO Conference

Provincial Government Building

Municipality of Maastricht

10 th Congress

European Association of NeuroOncology

September, 6-9, 2012

Marseille, France

CME Credits

The EANO has applied for credits at the European Accreditation

Council for Continuing Medical Education, Institution of the UEMS.

The number of credits (approx. 15 for the congress and 6 for the

educational day) will figure on the respective confirmation, which

will be sent after the meeting.

The rules of the EACCME state that participants are kindly asked to

fill in the feedback (evaluation) form included in the conference bag. It can be

returned to the registration desk.

Participants applying for credits will have to have their badge scanned daily at the

CME desk in the registration area before entering the conference. The

confirmation will be mailed after the conference beginning of October.

www.eano.eu 7

ACKNOWLEDGEMENTS


PROGRAMME AT A GLANCE

PROGRAMME AT A GLANCE

Time Auditorium 1 Auditorium 2 Room Brussels

Thursday, September 16, 2010 Educational Day (Registration will start at 08.30)

09.30–17.30 Educational Day

18.00–19.00 Satellite Symposium Merck Serono

(17.30 Welcome Drinks)

19.30–20.00 Welcome Reception Provincial Government Building

Friday, September 17, 2010

08.00–09.00 Meet The Experts Sessions Meet The Experts Sessions Meet The Experts Sessions

09.10–10.10 Neuro-Imaging (I) Glioblastoma multiforme and anaplastic glioma Molecular markers (I)

10.15–11.15 Brain and leptomeningeal metastasis Cell Biology / Immunotherapy Meningeoma and pediatric brain tumours

11.15–11.45 Coffee break Coffee break Coffee break

11.45–12.00 Official Opening of the Congress

12.00–13.30 Plenary Session: Drug delivery in animal and

human models – problems and possibilities

14.00–18.00 ROOM PARIS: Nurses Session

13.30–14.30 Lunch / Poster / Exhibition Lunch / Poster / Exhibition Lunch / Poster / Exhibition

14.30–15.30 Poster Viewing in the Poster/Exhibition Area

15.30–16.30 Presentation selected posters Presentation selected posters Presentation selected posters

16.30–17.00 Coffee break (Nurses: 15.30–16.00)

17.00–18.00 Symposia: New CNS lymphoma Trials

18.00–19.30 Satellite Symposium MSD Oncology

Saturday, September 18, 2010

08.00–09.00 Meet The Experts Sessions Meet The Experts Sessions Meet The Experts Sessions

09.10–10.10 Molecular markers(II) Neuro–Imaging (II) Supportive care

10.15–11.15 Glioma (10.15 – 11.25) Quality of Life Miscellaneous

11.15–11.45 Coffee break Coffee break Coffee break

11.45–13.15 Plenary Session: Global mining of cancer

through omics technologies

13.15–14.00 Lunch / Poster / Exhibition Lunch / Poster / Exhibition Lunch / Poster / Exhibition

14.00–15.00 Poster Viewing in the Poster/Exhibition Area

15.00–16.00 Presentation selected posters Presentation selected posters Presentation selected posters

16.00–16.30 Coffee break

16.30–17.30 Keynote Lecture: Germ cell tumours – biology and

treatment in children and adolescents

17.30–18.00 EANO General Assembly

18.00–19.00 Satellite Symposium F. Hoffmann-La Roche Ltd.

(17.30 Welcome Drinks)

20.00–24.00 EANO IX Party at the Kruisheren Hotel Maastricht

Sunday, September 19, 2010

08.30–10.00 ROOM COPENHAGEN: Symposium on Neuro-Oncology in Eastern European and Northern African Countries

10.00–11.00 Plenary Session: Advances in

surgery and radiotherapy

11.00–11.30 Coffee break

11.30–12.00 EORTC Clinical Trials Update

12.00–13.00 Keynote Lecture: Imaging PET and MR, early

treatment response

13.00–14.00 Communication Awards & Closing Remarks

8 www.eano.eu


SCIENTIFIC PROGRAMME

Time

09.00-

09.30

09.30

09.45

09.55

10.20

10.45

11.10-

11.40

11.40

11.45

12.10

12.35

13.00-

14.00

14.00

14.10

14.35

15.00

15.25

15.50-

16.20

16.20

16.25

16.50

17.15

17.30

Room/Auditorium 2

Educational Day

Decision Making in Low- and High-grade Gliomas

Evidence or Emotion Based?

Moderator: Charles J. Vecht

Coffee break

DIAGNOSIS AND THERAPY: STATE-OF-THE-ART

Setting the stage: What is evidence?, P. Leffers

Clinical Case part 1: Low grade glioma, D. Brandsma

Integrating MRI in the decision making: when to stop “wait and see” in low-grade

glioma, A.Waldman

EVOLUTION TO HIGH GRADE GLIOMA

Neuropathological diagnosis, P. Wesseling

Neurosurgery, C. Dirven

Coffee break

Clinical Case part 2: glioblastoma, D. Brandsma

Radiotherapy: The cornerstone of glioma treatment, L. Stalpers

Chemotherapy, M. van den Bent

Cognition, J. Heimans

Lunch

TUMOUR RECURRENCE

Clinical Case part 3: tumour recurrence, D. Brandsma

Recurrence vs. pseudo-progression, S. Sunaert

The role of re-operation in malignant glioma, P. Vandertop

Efficacy of re-irradiation, B. Baumert

Experimental therapy I, A. Griffioen

Coffee break

Clinical Case part 4: tumour re-recurrence, D. Brandsma

Experimental therapy II / Patient shopping, W. van der Graaf

Quality of Life and Quality of Care in the End-of-Life phase, M. Taphoorn

Conclusions & Discussion: evidence, emotion, reason, P. Leffers

Closure

www.eano.eu 9

THURSDAY, SEPTEMBER 16


THURSDAY, SEPTEMBER 16

SCIENTIFIC PROGRAMME

Time

18.00-

19.00

18.00

18.05

18.20

18.35

18.50

Room/Auditorium 2

Satellite Symposium Merck Serono

Integrin inhibition with cilengitide – a cutting-edge concept in glioblastoma

Chairs: M. van den Bent, The Netherlands

M. Weller, Switzerland

Refreshments will be served from 17.30.

Welcome and Introduction, M. Weller

Current treatment concepts in glioblastoma, M. van den Bent

Radiotherapy and Integrin inhibition, E. Cohen, J.Moyale

Ongoing clinical trials and the role of the MGMT assay, M. Weller

Discussion and closing remarks, M. van den Bent

Thursday, September 16, 2010, 19.30 – 21.00

Welcome Reception in the Provincial Government Building („Gouvernement aan de Maas“)

You will be served fingerfood and drinks while enjoying the beautiful atmosphere in the Provincial

Government Building of Maastricht.

Dress code: casual smart

Free for registered participants and accompanying persons.

Please note that advance registration is mandatory in order to receive a ticket!

Limited attendance!

ADDRESS: Limburglaan 10, 6229 GA Maastricht

HOW TO GET THERE: by walking 5-10 minutes from MECC – please see the map on the back side

of the invitation or ask at the registration desk.

TONGEREN TTT ON O ON OONGEREN

NNN NN N--

- HHHHA HHA HHH

HA

JEKER JEK JEKE KEE

N278 N2 N27 N278 N27 N278 8

Biesland B Bie Biesland ie iesl iesla ess

sl sla lla

lan a aan and nd d

John John F.Kennedybrug

F.Kennedybrug

RIVER MEUSSE

Entrance

EANO 2010

Welcome

Reception

2

P

Limburglaan

Sint Pieter

1

wijk 21

wijk 21-29

SE SE

John n F.

JJo o

JJJ

J F

F.

ee P

Kennedybrug bbbruuug g

Kee Kee

e bbb brug

KK bbbbbb

n

h

nn dy

e

ddd

ybbbb yb yb ybbb

yy

brru

P

Limburglaan

Limburglaan imburgla imburgla mbu mmbu mbur mburgl bu bu bbu

burgl burgl bur u gl ll

n

wijk w 21-29 MECC

P

S SSta Station

Station ta a ation

MECC M MECC

ECC

Ra R Ra R RRandwijc Ra RRandwijck

Ra Randwijc Ra Randwijck a aan

aandw and d ddw

dwi dwij dwi dwij

ijck ij ck

k

Randwyck R Ran Randwy Randwyck an

nd n nd ndw d dwyc wy wwyc

wy wyck yc y yyc

y ck k

Heugem H HHeu

He Heug Heugem eu eug uug

u uuge u uge g e eem

e em m

wijk w ij ijk

29 2 AZM AZ AZM

AZM

M

10 www.eano.eu

wijk wwijk wij wijk wij w k 21

P

A2 AA2

E25 25 2

Heer H He Heer e er

AALS A ALS L LS


SCIENTIFIC PROGRAMME

Time

08.00-

09.00

Time

09.10 -

10.10

Auditorium 1

Auditorium 2

Room Brussels

Meet The Experts Sessions: Meet The Experts Sessions: Meet The Experts Sessions:

A. Advances in research &

B. Advances in meningioma C. Predicting risk and outcome in

treatment of brain metastasis Chair: C. Dirven (Rotterdam, The glioma by genetics

Chair: R. Soffietti (Torino, Italy) Netherlands)

Chair: B. Melin (Umea,Sweden)

Speakers:

Speakers:

Speakers:

M. Brada (Sutton, UK)

S. Sadetzki (Ramat-Gan, Israel) B. Melin (Umea, Sweden)

R. Soffietti (Torino, Italy)

D. Peereboom (Cleveland, USA)

This session is kindly supported by

F. Hoffmann-La Roche Ltd.

G. Tomei (Varese, Italy)

M. Kalaramides (Paris,France)

R. Houlston (London, UK)

M. Sanson (Paris, France)

Auditorium 1

Auditorium 2

Room Brussels

Session: Neuro-Imaging (I) Session: Glioblastoma multiforme Session: Molecular markers (I)

Chair: L. Jacobi (The Netherlands), and anaplastic glioma

Chair: J. Jeuken (The

S. Sunaert (Belgium)

Chair: S. Short (United Kingdom), Netherlands), M. Sanson (France)

O.01 Influence of P-glycoprotein

expression on 99mTc-Tetrofosmin

uptake in gliomas

G. A. Alexiou, S. Tsiouris,

A. Goussia, A. P. Kyritsis,

S. Voulgaris, A. D. Fotopoulos

M. Weller (Switzerland)

O.07 MGMT promoter methylation

status and expression of DNA

mismatch repair genes in paired

primary and recurrent

glioblastoma – A translational

study of the

German Glioma Network

J. Tonn, J. Felsberg, N. Thon,

S. Eigenbrod, M. Westphal,

G. Schackert, M. Löffler, F. Kreth,

M. Weller, G. Reifenberger

O.13 Molecular malignant

progression in gliomas; elucidating

their genetic ‘life story’

A. Sijben, A. Navis, F. Bleeker,

S. H. E. Boots-sprenger,

J. Rijntjes, P. Wesseling,

J. W. M. Jeuken

O.02 Perfusion MR in

differentiating between tumorprogression

and

pseudo-progression in recurrent

glioblastoma multiforme

C. Heidemans - Hazelaar,

B. van der Kallen, A. Y. Verbeek -

de Kanter, C. J. Vecht

O.03 Assessment of Bevacizumab

/Irinotecan response in malignant

glioma by ADC map image

analysis

M. Nowosielski, M. Hutterer,

G. Tinkhauser, H. Kostron,

G. Goebel, W. Recheis,

G. Stockhammer, T. Gotwald

O.04 Radiographic Patterns of

Relapse in Glioblastoma

M. Chamberlain

O.05 Preoperative estimation of

extent of resection of gliomas by

DTI FT

G. Casaceli, A. Castellano,

C. Michelozzi, G. Bertani, E. Fava,

G. Carrabba, A. Falini, L. Bello

O.06 Usefulness of MET-PET, FLT-

PET and FMISO-PET for Surgical

Treatment of Gliomas

K. Miyake, M. Okada, N. Kawai,

T. Tamiya

O.08 MGMT mRNA transcriptional

activity predicts clinical outcome in

malignant gliomas after radio-

/chemotherapy

N. Thon, S. Kreth, S. Eigenbrod,

H. Kretzschmar, J. Tonn, F. Kreth

O.09 Updated Response

Assessment Criteria For High-

Grade Gliomas (HGG) – report

from theResponse Assessment in

Neuro-Oncology (RANO) Working

Group

M. van den Bent, D. MacDonald,

S. Chang, M. A. Vogelbaum,

P. Y. Wen

O.10 A prospective, randomized,

open label, phase III clinical trial

of NovoTTF-100A versus best

standard of care chemotherapy in

patients with recurrent

glioblastoma

R. Stupp, A. Kanner,

H. Engelhard, V. Heidecke,

S. Taillibert, F. Lieberman,

V. Dbaly, E. D. Kirson, Y. Palti,

P. H. Gutin

O.11 Stem/progenitor cell

flexibility determines both normal

brain development and brain

tumors

P. Sathyan, M. Kamal, S. Singh,

F. Robinson, S. Majumder

O.12 Efficient Engraftment of

MGMTP140K gene-modified

CD34+ Cells Following

Nonmyeloablative BCNU

Conditioning in Patients with

Glioblastoma

M. M. Mrugala, J. E. Adair,

B. C. Beard, J. K. Rockhill,

D. L. Silbergeld, R. Rostomily,

P. Becker, M. C. Chamberlain,

A. Spence, H. Kiem

O.14 Comparison of MS-PCR,

MethyLight, pyrosequencing, MS-

HRM and immunohistochemistry

for MGMT analysis

V. Quillien, E. Bellissant,

M. Sanson, L. Karayan-Tapon,

T. Lesimple, O. Chinot,

C. Carpentier, F. Fina,

D. Figarella-Branger

O.15 Transcriptional inactivation

and promoter hypermethylation of

the tumour suppressor gene

NDGR2 in high grade

oligodendroglial tumours

Y. Ruano, Á. Rodríguez de Lope,

E. Pérez-Magán, A. García-Claver,

Y. Campos-Martín, C. Fiaño,

T. Ribalta, J. F. García, M. Mollejo,

B. Meléndez

O.16 A four-gene signature

associated with clinical outcome in

high-grade gliomas

M. Aubry, M. de Tayrac,

S. Saïkali, A. Etcheverry,

A. Hamlat, T. Lesimple, V. Quillien,

P. Menei, J. Mosser

O.17 Expression of telomerase

reverse transcriptase (hTERT) in

human glioblastoma specimen is

associated with shorter patient

survival and is a prerequisite for in

vitro immortalization

S. Spiegl-Kreinecker, D. Lötsch,

M. Wild, C. Pirker, J. Pichler,

R. Silye, S. Weis, J. Fischer,

M. Micksche, W. Berger

O.18 IDH1 mutations in gliomas:

correlation with genomic profile

and prognosis

X. Wang, M. Labussiere,

B. Boisselier, C. Ottolenghi,

D. Rabier, D. Ricquier, Y. Marie,

J. Delattre, M. Sanson

www.eano.eu 11

FRIDAY, SEPTEMBER 17


FRIDAY, SEPTEMBER 17

SCIENTIFIC PROGRAMME

Time

10.15 -

11.15

11.15 -

11.45

Auditorium 1

Session: Brain and

leptomeningeal metastasis

Chair: B. Baumert (The

Netherlands), W. Boogerd (The

Netherlands)

O.19 Prospective multicentric

validation of a survival prognostic

index in leptomeningeal

carcinomatosis – Analysis interim

of the ACME study

J. Bruna, M. Navarro, E. Millastre,

P. Salinas, M. Provencio, N.

Martínez, I. Garau, M. Domine,

D. Subira, M. Gil

O.20 Neoplastic meningitis – value

of MRI and protein analysis and

patterns of lymphomatous

cytomorphology

H. M. Strik, P. Proemmel,

C. Perske, H. Nagel

O.21 Case Series of Frameless

Linear Accelerator-based

Stereotactic Radiosurgery to the

Postoperative Resection Cavity for

Brain Metastasis-an initial report

of outcomes and patterns of

failure

P. J. Kelly, Y. B. Lin, A. Y. C. Yu,

D. J. Sher, F. L. Hacker,

K. J. Marcus, S. E. Weiss

O.22 Treatment of brain

metastases from non-small cell

lung cancer with whole brain

radiotherapy (WBRT) in

combination with gefitinib (GFT) or

temozolomide (TMZ). A

randomized multicenter phase II

trial of the Swiss Group of Clinical

Cancer Research (SAKK #70/

G. A. Pesce, R. Von Moos,

G. D’Addario, C. B. Caspar,

N. Fischer, S. Anchisi, N.

Kotrubczik, A. Zouhair, M. Mayer,

R. Stupp

O.23 Frequency, patterns of care

and outcome of neoplastic

meningitis (NM) from solid tumors

in the Regione Piemonte, Italy: a

prospective survey from a cancer

network

R. Rudà, L. Bertero, E. Picco,

E. Trevisan, L. Tarenzi,

M. Donadio, M. Airoldi,

O. Bertetto, C. Mocellini,

R. Soffietti

O.24 Stemcell transplantation for

CNS recurrence of systemic NHL –

an International Primary CNS

Lymphoma Group (IPCG) project

J. E. C. Bromberg, K. Jahnke,

G. Illerhaus, L. Fischer, K. Fritsch,

O. Kuittinen, S. Issa, J. Doorduijn,

E. Thiel, M. J. van den Bent,

F. Termorshuizen

Coffee Break / Poster viewing / Exhibition

Auditorium 2

Session: Cell Biology /

Immunotherapy

Chair: W. van der Graaf (The

Netherlands), M. Westphal

(Germany)

O.25 Bone marrow-derived cells

dynamically interact with glioma

cells during tumor invasion and

angiogenesis

F. Winkler, L. von Baumgarten,

Y. Kienast, J. Herms

O.26 Notch pathway blockade

affects the migratory and

differentiating capacity of brain

tumor initiating cells

K. Kristoffersen, M. Stockhausen,

H. S. Poulsen

O.27 NG2 promotes resistance to

ionising radiation by elevated

peroxiredoxin-1 and DNA damage

response in glioblastoma

multiforme

M. Chekenya, I. Netland,

J. J. Verhoeff, A. Svendsen,

J. Brøgger, H. Immervoll,

J. Planaguma, A. Bohne-Kjersem,

P. Sakarriassen, R. Bjerkvig,

J. I. heggedal, P. Enger,

K. J. Tronstad, W. Van Furth

O.28 CD44 loss of function

impedes glioma progression in a

spontaneous murine model

S. Decker, J. McCarthy, C. Forster,

K. SantaCruz, J. Ohlfest

O.29 Therapeutic targeting of the

NG2 proteoglycan with mAb

9.2.27 and adoptively transferred

NK cells lyses human glioblastoma

multiforme in vivo

M. Chekenya, J. Wang, A. Poli,

M. Thuen, C. Brekke, F. Thorsen,

J. Zimmer, P. Enger

O.30 Phase III anti-EGF-receptor

antibody (OSAG-101) for newly

diagnosed glioblastoma : Safety

and Current Status

M. Westphal, C. Senft, C. Braun,

T. Pietsch, M. Warmuth, F. Bach,

O. Heese

Room Brussels

Session: Meningeoma and

pediatric brain tumours

Chair: R. D. Kortmann (Germany),

S. Leenstra (The Netherlands)

O.31 The effect of edema on

health-related quality of life in

WHO grade I meningioma patients

D. van Nieuwenhuizen,

L. Bosscher, E. Szymanska,

J. J. Heimans, S. M. Peerdeman,

M. Klein, J. C. Reijneveld,

O.32 Hypofractionated stereotactic

radiotherapy of the optic nerve

sheath meningiomas: an effective

option

L. Fariselli, M. Marchetti, I.

Milanesi, L. Bianchi, A. Bergantin,

S. Bianchi, S. Giombini,

A. Franzini, G. Broggi, C. L. Solero

O.33 Survival and functional

outcome of meningioma patients:

Long-term disability and poor

survival

M. M. de Leau, H. van Alkemade,

W. van Furth, W. P. van der Top,

L. J. A. Stalpers

O.34 Second-Look Surgery (SLS)

for ependymoma: The italian

experience

M. Massimino, M. L. Garrè,

C. L. Solero, A. Cama, L. Genitori,

C. Di Rocco, I. Sardi, E. Viscardi,

P. Modena, S. Barra, G. Scarzello,

E. Galassi, F. Giangaspero,

L. Gandola

O.35 Thirty-five years of surgically

treated pediatric meningiomas in

the Netherlands. A descriptive

epidemiological case study

N. B. Thuijs, B. M. J. Uitdehaag,

P. van der Valk, S. M. Peerdeman

O.36 Dose constraint model to

predict neurocognitive outcomes in

young patients with low grade

brain tumours treated with

stereotactic conformal

radiotherapy

R. Jalali, S. Goswami, T. Gupta,

D. Dutta, R. Sarin

12 www.eano.eu


SCIENTIFIC PROGRAMME

Time

11.45-

12.00

12.00-

13.30

13.30-

14.30

Time

14.00-

18.00

14.30-

15.30

Auditorium 1

Official Opening of EANO IX

Welcoming addresses

Plenary Session:

Drug delivery in animal and human models – problems and possibilities

Chair: R. Henriksson (Umea, Sweden), C. Herold-Mende (Heidelberg, Germany)

Animal modeling, S. Niclou (Luxembourg, Luxembourg)

Local delivery in animal and human models, T. Siegal (Jerusalem, Israel)

Gene therapy, C. Dirven (Rotterdam, Netherlands)

Lunch / Poster viewing / Exhibition

Room Paris

Nurses Session (see extra programme page 16)

Poster viewing with presenters

TOPICS:

01. Cell biology and signalling ...................................................................P.01-15

02. Epidemiology.....................................................................................P.16-19

03. Quality of life.....................................................................................P.20-32

04. Immunology and immunotherapy.........................................................P.33-37

05. In vitro / in vivo models......................................................................P.38-39

06. Predictive biomolecular markers...........................................................P.40-54

07. New drug delivery methods......................................................................P.55

08. Neuroimaging of brain tumours............................................................P.56-68

09. Glioblastoma multiforme and Anaplastic gliomas (I)................................P.69-90

www.eano.eu 13

FRIDAY, SEPTEMBER 17


FRIDAY, SEPTEMBER 17

SCIENTIFIC PROGRAMME

Time

15.30 -

16.30

Auditorium 1

Presentation Selected Posters

Session: Neuro-Imaging

Chair: L. Bello (Italy), P. Hofman

(The Netherlands)

P.056 Routine follow up imaging

after treatment for Glioblastoma:

How useful is it?

D. Nesbitt, G. Hendry, D. Scoones,

P. Kane

P.057 Peri-Ictal Pseudoprogression

in Brain Tumour Patients

S. Rheims, F. Ducray, L. Taillandier,

D. Ricard, V. Bourg, V. Desestret,

S. Cartalat-Carel, M. Sanson, J.

Honnorat

P.058 Correlation of vestibular

schwannoma volume with growth

and auditory function in a wait and

scan policy

R. van de Langenberg,

B. J. de Bondt, P. J. Nelemans,

A. J. C. Dohmen, B. G. Baumert,

R. J. Stokroos

P.059 MRI and Thallium-201

SPECT in the prediction of

outcome in glioma therapy

M. J. Vos, J. Berkhof, O. S. Hoekstra,

I. Bosma, E. M. Sizoo, J. J. Heimans,

J. C. Reijneveld, E. Sanchez,

F. J. Lagerwaard, J. Buter,

D. P. Noske, T. J. Postma

P.060 Analysing response of

malignant glioma to bevacizumab

using high-resolution magnetic

resonance imaging at 7 Tesla

G. Grabner, I. Nöbauer, K. Elandt,

C. Marosi, S. Trattnig, M. Preusser

P.061 Value of Thallium SPECT

(SPECT) to evaluate response to

bevacizumab treatment in highgrade

glioma (HGG) patients

C. Balaña, V. Vallejos, S. Villà,

S. Domenech, O. Etxaniz,

I. Cardiel, C. Hostalot

P.062 Preservation of pyramidal

tract by Navigation-assisted

Intraoperative mapping in glioma

surgery

F. Yamaguchi, T. Kojima,

H. Takahashi, A. Teramoto

P.063 Magnetic resonance imaging

of viral spread and intratumoral

inflammation during oncolytic

virotherapy

A. Kleijn, J. W. Chen, P. Z. Sun,

J. Buhrman, S. D. Rabkin,

R. Weissleder, R. L. Martuza,

M. L. Lamfers, G. Fulci

P.148 The role of temozolomide

for patients with metastatic brain

disease

D. R. Naskhletashvili, V. Gorbunova,

M. Bychkov, D. Rzaev, G. Chmutin,

V. Karakhan, V. Aloshin, Z. Michina,

S. Alieva, E. Moskvina

Auditorium 2

Presentation Selected Posters

Session: GBM/Anaplastic astrocytoma

Chair: M. ter Laak (The Netherlands),

R. Stupp (Switzerland)

P.069 Prognostic Impact of Stem

Cell Marker CD133 in 61 Glioblastoma

Patients Treated with

Concomitant Radiochemotherapy:

A Prospective Study

P. Metellus, I. Nanni-Metellus,

C. Delfino, C. Colin, B. Coulibaly,

F. Fina, O. Chinot, D. Figarella-

Branger, L. Ouafik

P.070 Pattern of recurrence and

pseudo-progression in glioblastoma

patients treated with postoperative

radiotherapy with concurrent

temozolomide

E. Van Mieghem, A. Wozniak,

Y. Geussens, J. Menten, S. De

Vleeschouwer, F. Van Calenbergh,

R. Sciot, J. Lobelle, P. Clement

P.071 Can OS-6 replace PFS-6 as a

primary endpoint in phase II studies

on glioblastoma patients given

antiangiogenetic drugs?

E. Franceschi, A. A. Brandes,

A. Tosoni, A. Bacci, G. Crisi,

F. Spagnolli, F. Alessandrini,

S. Bartolini, R. Poggi, M. Ermani

P.072 A phase III randomized

controlled trial of short-course

radiotherapy with or without

concomitant and adjuvant

temozolomide in elderly patients

with glioblastoma multiforme

J. R. Perry, C. J. O’Callaghan,

K. Ding, A. A. Brandes, C. Phillips,

J. Menten, M. Fay, R. Nishikawa,

C. Winch, N. Laperriere

P.073 Influence of hypoxia on

glioma and glioma stem-like cells

M. Sanzey, A. Golebiewska,

L. Vallar, S. Niclou

P.074 Circulating Endothelial Cells

decrease significantly in relapsing

high grade glioma patients

responding to bevacizumab.

M. Eoli, A. Calleri, L. Cuppini,

E. Mancuso, E. Prodi, S. Pellegatta,

P. Porrati, M. Bruzzone, F. Bertolini,

G. Finocchiaro

P.075 The expression of NG2

identifies a tumour competent

population in glioblastoma with

distinct molecular signature

T. Fael Al-Mayhani, E. Kenny-Herbert,

K. Ichimura, P. Collins, C. Watts

P.076 Neoadjuvant temozolomide

for grade III and IV atrocytoma: a

randomized phase II study

A. Malmstrom, H. Skovgaard

Poulsen, G. Stragliotto, B. Gronberg,

S. Hansen, T. Asklund,

R. Henriksson

Room Brussels

Presentation Selected Posters

Session: Miscellaneous

Chair: T. Seute (United Kingdom),

B. Melin (Sweden)

P.033 Intense human

cytomegalovirus (HCMV) immune

response in glioblastoma patients:

A novel prognostic factor for

survival

A. García-Velasco, R. Fuentes,

J. Marruecos, J. Menendez,

J. Brunet

P.034 Modulating the IL-1

signaling during glioma oncolytic

virotherapy

G. Fulci, A. Kleijn, J. Buhrman,

S. Collins, M. Lamfers, S. Rabkin,

R. Martuza

P.151 Subacute neurological

syndrome with imaging correlate

following intrathecal methotrexate

in an adult

G. von Geldern, M. M. Mrugala,

B. Distad

P.038 Establishment of

temozolomide-refractory glioma

cells

Y. Hong

P.039 High-Resolution NMR

Spectroscopy of Brain-Derived

Stem Cells

P. Ramm, A. Vollmann-Zwerenz,

P. Kumar, L. Aigner, U. Bogdahn,

H. Kalbitzer, P. Hau

P.055 GSH-conjugation improves

efficacy of Doxil against

intracranial xenografts

O. van Tellingen, D. Brandsma,

W. Boogerd, C. Appeldoorn,

F. Manca, J. Rip, R. Dorland,

J. van Kregten, P. Gaillard

P.001 Protein tyrosine

phosphatases in glioma biology

A. C. Navis, J. W. J. Jeuken,

J. T. G. Schepens, B. Celda,

V. Esteve, W. P. Leenders,

P. Wesseling, W. J. A. J. Hendriks

P.040 Screening chemotherapy

agents using surgically obtained

brain tumor specimens

J. F. Megyesi, P. Costello,

W. Macdonald, E. Dyer,

D. Macdonald, R. Hammond,

Y. Kalache, J. McIntyre, J. Easaw

P.035 T-cell based identification of

tissue antigens by automated twodimensional

protein fractionation

C. C. Herold-Mende, R. Warta,

R. Ahmadi, M. Schnölzer,

A. Unterberg, P. Beckhove

14 www.eano.eu


SCIENTIFIC PROGRAMME

Time

16.30 -

17.00

Time

17.00-

18.00

Time

18.00-

19.30

Auditorium 1

Auditorium 2

P.077 Cancer stem cells in

Glioblastoma, what are they?

A. Golebiewska, N. H. Brons,

R. Bjerkvig, S. P. Niclou

Coffee Break / Poster viewing / Exhibition

Auditorium 1

Symposia: New CNS lymphoma Trials

Chair: K. Hoang Xuan (Paris, France)

Auditorium 2

P.124 Prox1 is a predictor of

survival for astrocytic gliomas but

not for oligodendrogliomas grade

II

T. Elsir, M. Qu, S. Berntsson,

A. Orrego, T. Olofsson, M. Lindström,

M. Nister, D. Ribom, A. Smits

Room Brussels

G-PCNSL-SG-1 randomized phase IV trial on the role of whole brain radiotherapy in

primary cerebral lymphoma, M. Weller (Zurich, Switzerland)

Intensive chemotherapy with hematopoietic stem cell rescue for PCNSL, C. Soussain

(Paris, France)

I.E.L.S.G. trials in PCNSL, A. Ferreri (Milano, Italy)

Satellite Symposium MSD Oncology

PERSPECTIVES ON GBM: THE CHALLENGES OF TREATING MALIGNANT GLIOMAS

Chair: Martin van den Bent, MD, Rotterdam Cancer Center, Erasmus University

Hospital, The Netherlands

SYMPOSIUM AGENDA:

Perspectives on the Treatment of Elderly Patients with GBM

The Nordic Trial

Annika Malmström, MD, Unit of Advanced Palliative Home Care, Linköping University

Hospital, Sweden

The NOA 8 Trial

Wolfgang Wick, MD, Department of Neuro-oncology, University of Heidelberg, Germany

Management of Elderly GBM Patients in 2010

Roy Rampling, MD, Division of Cancer Sciences and Molecular Pathology, University of

Glasgow, Scotland

Perspectives on the Treatment of Grade III Tumors

Management of Grade III Tumors After NOA 4

Martin van den Bent, MD, Rotterdam Cancer Center, Erasmus University Hospital, The

Netherlands

www.eano.eu 15

FRIDAY, SEPTEMBER 17


FRIDAY, SEPTEMBER 17

SCIENTIFIC PROGRAMME

Time

14.00

14.10

14.50

15.10

15.30-

16.00

16.00

16.20

16.40

17.00

17.20

17.55

Room Paris

Nurses Session EANO IX

Welcome

Shanne McNamara, Western General Hospital Edinburgh, UK

“What’s the point?” Exploring the purpose of Physiotherapy Rehabilitation for patients

with Primary Brain Tumours: An Ethnographic study of patients’ perspectives.

Diz Hackman, The Royal Marsden NHS Foundation Trust, UK

The Neuro-oncology Patient Concerns Inventory.

Ally Rooney The Western General Hospital Edinburgh UK

Anouk Netten, Leiden University Medical Centre, The Netherlands

Is the Distress Thermometer Useful in Glioma Patients?

Sandra Bossmann, Raboud University Hospital Nijmegen, The Netherlands

Coffee break

Using Case Study Design to Explore the Management of Patients with Metastatic

Spinal Cord Compression (MSCC).

Siew Hwa Lee, Edinburgh Napier University / Western General Hospital, UK

The Challenges for a Specialist Nurse in Northern Sweden

Agneta Spetz, University Hospital Umeå, Sweden

Low Grade Glioma and Changes in Personality and Character: Difficulties in

Maintaining Relationships.

Lies Braam and Hanneke Zwinkels, Medical Centre Haaglanden Den Haag, The

Netherlands

Caring for Patients with Cancer at Home – the Tuscan Experience

Helen Limborgh Meijer, Tuscany, Italy

Working collaboratively to Prioritise Research to Enhance Patient Care in

Neuro-oncology.

Lynn Kilbride, Edinburgh Napier University, UK

Closing Remarks

Shanne McNamara, Western General Hospital Edinburgh, UK

16 www.eano.eu


SCIENTIFIC PROGRAMME

Time

8.00-

9.00

Time

09.10 -

10.10

Auditorium 1

Auditorium 2

Meet The Experts Sessions: Meet The Experts Sessions:

A. Late effects of neurooncology B. Molecular radiation biology in

treatment

glioma

Chair: W. Grisold (Vienna, Austria) Chair: S. Short (London, UK)

Speakers:

Speakers:

M. Taphoorn (The Hague,

A. Chalmers (Brighton, UK),

Netherlands),

B. Wouters (Toronto, ON, Canada),

H. Spoudeaus (London, UK), G. Frosina (Genova, Italy)

G. Cavaletti (Monza, Italy)

This session is kindly supported by

Merck Serono.

Auditorium 1

Auditorium 2

Session: Molecular markers (II) Session: Neuro-Imaging (II)

Chair: A. Gijtenbeek (The

Chair: M.C. Hoeberigs (The

Netherlands), B. W. Kristensen Netherlands), M. Bendszus

(Denmark)

(Germany)

O.37 CI-PERINOMS:

O.43 Hot spots in 18FET-PET

Chemotherapy-Induced Peripheral delineate malignant tumour parts

Neuropathy Outcomes Measures within suspected WHO grade II

Study

glioma

G. Cavaletti

M. Kunz, N. Thon, S. Eigenbrod,

C. Hartmann, J. Geisler,

H. Kretzschmar, A. von Deimling,

G. Pöpperl, J. Tonn, F. Kreth

O.38 Glut1/SLC2A1 is crucial for

development of brain

microvasculature with blood brain

barrier (BBB) properties in vivo:

potential clinical implications

P. Zheng, E. Romme, P. J. van der

Spek, C. M. Dirven, R. Willemsen,

J. M. Kros

O.39 TIMP-1 and the TIMP-1

interacting cell surface protein

CD63 in cultured astrocytoma

derived spheroids: expression and

co-expression with stem cell

markers

C. Aaberg-Jessen, S. S. Jensen,

H. D. Schrøder, C. Andersen,

N. Brünner, B. W. Kristensen

O.40 Myelodysplasia in Primary

Brain Tumor Patients treated with

Alkylating Agents

J. M. Baehring

O.41 Chemotherapy-induced

Polyneuropathy Score (CIPS) –

A new tool in the diagnosis of

Chemotherapy-induced

Polyneuropathy (CIPN)

A. Grisold, W. Grisold, C. Dittrich,

S. Oberndorfer

O.42 The potential role of vascular

endothelial growth factor in

radiation necrosis of the brain,

from the pathological

consideration of human surgical

specimen

S. Miyatake, M. Furuse,

R. Hiramatsu, N. Nonoguchi,

S. Kawabata, T. Kuroiwa,

M. Fukumoto, M. Fukumoto,

K. Ono

O.44 Language mapping findings

and correlation with DTI FT data

during surgical removal of lesions

involving language areas or

pathways

L. Bello, A. Castellano, G. Casaceli,

F. Portaluri, E. Fava, A. Casarotti,

C. Papagno, A. Falini

O.45 Usefulness of NMR based

metabolomics (metabolome) using

the analysis of water and lipidsoluble

metabolites as the

predictive factors of malignant

type meningiomas

H. Takahashi, K. Hirakawa,

F. Yamaguchi, Y. Ohno,

A. Teramoto

O.46 Intraobserver and

interobserver agreement in

volumetric assessment of

glioblastoma multiforme resection

P. L. Kubben, A. A. Postma,

A. G. H. Kessels, J. J. van

Overbeeke, H. van Santbrink

O.47 18F-Fluorothymidine (FLT)

Positron Emission Tomography to

determine the proliferative tumor

volume in high grade glioma and

correlation with survival

A. J. S. Idema, H. Boogaarts,

A. L. Hoffmann, A. Grotenhuis,

W. T. A. van der Graaf,

A. Heerschap, A. Kappelle,

P. Wesseling, W. J. Oyen

O.48 Early progression between

surgery and adjuvant chemoradiotherapy

in glioblastoma

D. Amelio, P. Farace,

G. K. Ricciardi, F. B. Pizzini,

G. Zoccatelli, F. Alessandrini,

A. Talacchi, M. Amichetti,

A. Beltramello

Room Brussels

Meet The Experts Sessions:

C. Treatment of elderly glioma

patients

Chair: W. Wick (Zurich, Switzerland)

Speakers:

M. Hohenegger (Vienna, Austria),

A. Malmström (Linköping,

Sweden),

W. Wick (Heidelberg, Germany)

This session is kindly supported by

MSD Oncology

Room Brussels

Session: Supportive care

Chair: B. Müller (Germany),

H. Tjon-a-Fat (The Netherlands)

O.49 Identifying clinical depression

in patients with brain tumours

A. G. Rooney, S. McNamara,

M. Mackinnon, M. Fraser,

R. Rampling, A. Carson, R. Grant

O.50 Psychological factors of the

retardation of mental development

in children with recurrent brain

tumors.

J. V. Malova

O.51 A HADS depression subscale

score ≥8 can help screen for

depression in adults with primary

glioma.

A. G. Rooney, S. McNamara,

M. Mackinnon, M. Fraser,

R. Rampling, A. Carson, R. Grant

O.52 Screening for Cognitive

Impairment in Primary Brain

Tumour: is the Montreal Cognitive

Assessment a more sensitive tool

than the Mini Mental State

Examination?

H. Ke, E. Koh, G. K. Simpson,

D. Whiting, K. M. Wright,

T. Simpson

O.53 How to best meet the needs

of patients with a glioblastoma and

their families: screening for

psychosocial distress or a standard

consultation with a social worker

as part of their medical treatment

M. Krutzen, A. Speijcken,

T. Hooijen, H. Tjon-a-Fat,

R. Houben, F. van Gils,

B. G. Baumert

O.54 Epilepsy at the end of life in

malignant gliomas

A. Pace, C. Di Lorenzo,

L. Guariglia, M. Maschio,

T. Koudriavtseva, A. Pompili,

C. Carapella

www.eano.eu 17

SATURDAY, SEPTEMBER 18


SATURDAY, SEPTEMBER 18

SCIENTIFIC PROGRAMME

Time

10.15 -

11.15

11.15 -

11.45

Auditorium 1 (10.15-11.25)

Session: Glioma

Chair: A. Idbaih (France),

O. Schijns (The Netherlands)

O.55 IFN-β sensitizes glioma cells

to temozolomide in a MGMT- and

p53-independent manner

C. Happold, P. Roth, B. Adams,

K. Frei, G. Tabatabai,

H. Bertalanffy, M. Weller

O.56 Relationship to different cells

of origin predicts the TGF-beta

responsiveness of glioblastoma

cancer stem cells

P. Kumar, C. P. Beier, K. Meyer,

I. Aschenbrenner, P. Leukel,

P. Rümmele, P. Hau,

J. Wischhusen, R. Spang, D. Beier

O.57 Sunitinib malate as a single

agent or combined with lomustine

(CCNU) in patients with recurrent,

temozolomide refractory highgrade

glioma

B. Neyns, S. Lv, C. Chaskis,

J. Sadones, M. Dujardin,

H. Everaert, J. Duerinck,

N. Nupponen, A. Michotte,

J. De Greve

O.58 Non-R132 mutations in IDH1

identify a novel subgroup of lowgrade

gliomas with distinctive

location, infiltrative behavior,

dismal outcome and unique

molecular pattern

P. Metellus, C. Colin, B. Coulibaly,

Y. Marie, B. Boisselier,

K. Mokhtari, A. Barlier, O. Chinot,

D. Figarella-Branger

O.59 Dynamic history of low grade

gliomas treated with first-line PCV

chemotherapy

M. Peyre, S. Cartalat-Carel,

D. Meyronet, D. Ricard, A. Jouvet,

J. Pallud, K. Mokhtari, J. Guyotat,

E. Jouanneau, M. Sunyach,

D. Frappaz, J. Honnorat, F. Ducray

O.60 Which molecular signatures

predict progression-free survival

after surgery alone in patients

with low-grade gliomas?

M. Weller, B. Hentschel, J. Tonn,

J. Schramm, M. Westphal,

M. Löffler, A. von Deimling,

C. Hartmann

O.61 A comprehensive study of

the association between the EGFR

and ERBB2 genes and glioma risk

U. Andersson, J. Scwartzbaum,

F. Wiklund, S. Sjöström, Y. Liu,

S. Tsavachidis, A. Ahlbom,

A. Auvinen, H. Collatz-Laier,

M. Feychting, C. Johansen,

A. Kiuru, S. Lönn,

M. J. Schoemaker, A. J. Swerdlow,

R. Henriksson, M. Bondy, B. Melin

Coffee Break / Poster viewing / Exhibition

Auditorium 2

Session: Quality of life

Chair: S. Oberndorfer (Austria),

M. Taphoorn (The Netherlands)

O.62 Cognitive deficits in patients

with gliomas in eloquent areas

before and after awake surgery

J. F. Vork, A. J. P. E. Vincent,

C. M. F. Dirven, E. G. Visch-Brink

O.63 Quality of life in high-grade

glioma patients and their relatives

in the end-of-life phase

E. M. Sizoo, J. C. Reijneveld,

H. R. W. Pasman, J. J. Heimans,

L. Deliens, M. J. B. Taphoorn

O.64 Malignant glioma patient and

caregiver congruence in quality of

life reporting

D. I. Jacobs, S. A. Grimm,

A. Rademaker, L. Rice,

J. P. Chandler, K. Muro,

R. M. Levy, M. I. Marymont,

I. B. Helenowski, L. I. Wagner,

J. Raizer

O.65 Predictors of quality of life of

partners of high-grade glioma

patients

W. Hoeben, K. Hilverda,

J. J. Heimans, M. J. B. Taphoorn,

T. J. Postma, J. Buter, J. Lenting,

E. H. Collette, J. C. Reijneveld,

M. Klein

O.66 Glioblastoma in Elderly

patients: Health Related Quality of

Life (HRQoL) in a randomized trial

comparing 6-weeks of

Radiotherapy (RT) versus

hypofractionated RT over 2 weeks

versus Temozolomide

Chemotherapy (TMZ)

A. Malmstrom, B. Gronberg,

R. Stupp, C. Marosi, D. Frappaz,

H. Schultz, U. Abacioglu,

R. Henriksson

Room Brussels

Session: Miscellaneous

Chair: C. Dirven (The

Netherlands), R. Soffietti (Italy)

O.67 Have clinical features and

treatment outcome of 166 patients

with neurolymphomatosis (NL)

changed over a period of 36 years?

Assessment of a contemporary

International Primary CNS

Lymphoma Collaborative Group

(IPCG) series and literature case

review

B. Avni, S. Grisariu,

T. T. Batchelor, M. J. van den

Bent, F. Bokstein, D. Schiff,

O. Kuittinen, M. C. Chamberlain,

P. Roth, A. Nemets, E. Shalom,

D. Ben-Yehuda, T. Siegal

O.68 Efficacy of tailored treatment

for high and low risk

medulloblastoma in adults: A large

prospective phase II trial

A. A. Brandes, E. Franceschi,

A. Tosoni, E. Pozzati, R. Agati,

A. Maestri, C. Ghimenton,

B. Masotto, G. Rubboli, M. Ermani

O.69 Plasma IgE levels correlate

with the diagnosis and prognosis

of glioma patients

T. Jiang, Y. Lin, G. Zhang,

B. Chen, J. Xie

O.70 Anti-angiogenic treatment in

a clinically relevant glioblastoma

model reduces blood flow and

increases tumor cell invasion

O. Keunen, M. Johansson,

A. Oudin, M. Sanzey, S. A. Binti

Abdul Rahim, F. Fack, F. Thorsen,

T. Taxt, J. Wang, R. Bjerkvig,

S. P. Niclou

O.71 The quest for HuD specific T

cells – attempts to generate a HuD

specific T cell line

A. H. C. de Jongste, M. T. de

Graaf, P. D. M. van den Broek,

J. W. Gratama, P. A. E. Sillevis

Smitt

O.72 Combined use of monopolar

and bipolar motor mapping

findings and correlation with DTI

data during surgical removal of

lesions involving motor pathways

L. Bello, A. Castellano, G. Casaceli,

F. Portaluri, E. Fava, M. Riva,

A. Falini

18 www.eano.eu


SCIENTIFIC PROGRAMME

Time

11.45-

13.15

13.15-

14.00

14.00-

15.00

Auditorium 1

Plenary Session:

Global mining of cancer through omics technologies

Chair: A. von Deimling (Heidelberg, Germany), B. Melin (Umea, Sweden)

Molecular/ biological processes governing development of cancer, K. Aldape (Houston,

TX, USA)

IDH-1 and its role in glioma, A. von Deimling (Heidelberg, Germany)

Integrative genome-wide analysis in GBM, M. de Tayrac (Paris, France)

Lunch / Poster viewing / Exhibition

Poster viewing with presenters

TOPICS:

09. Glioblastoma multiforme and Anaplastic gliomas (II) ...........................P. 91-123

10. Low grade gliomas..........................................................................P.124-128

11. Pediatric brain tumours ...................................................................P.129-133

12. Meningiomas..................................................................................P.134-139

13. Spinal cord tumours........................................................................P.140-145

14. Brain and leptomeningeal metastases................................................P.146-150

15. Neurotoxicity and neuroprotection ....................................................P.151-152

16. Paraneoplastic neurological syndromes ..............................................P.153-155

17. Supportive and palliative care ..........................................................P.156-158

18. Primary central nervous system lymphoma (PCNSL)............................P.159-160

19. New developments in surgery .................................................................P.161

20. New developments in radiotherapy ...................................................P.162-165

21. Miscellaneous.................................................................................P.166-180

www.eano.eu 19

SATURDAY, SEPTEMBER 18


SATURDAY, SEPTEMBER 18

SCIENTIFIC PROGRAMME

Time

15.00-

16.00

16.00 -

16.30

Auditorium 1

Auditorium 2

Presentation Selected Posters Presentation Selected Posters

Session: Miscellaneous brain Session: Cell

tumours

biology/Immunotherapy

Chair: J. Bromberg (The

Chair: P. Wesseling (The

Netherlands), C. Walker (United Netherlands), H. M. Strik

Kingdom)

(Germany)

P.146 Route of intracerebrospinal P.002 Down-regulation of

fluid liposomal cytarabine

membrane protein uPARAP makes

administration, safety and efficacy glioma cells immobile and can be a

of therapy in neoplastic meningitis target for novel glioma therapy

J. Pardo, C. Ruiz-Ocaña,

S. Takahashi, T. Kawase, M. Toda

L. González-Cortijo, C. Aláez-Usón

P.003 Metabolomic

characterisation of stem-like

glioblastoma cell lines

S. C. Dietz, J. Griffiths, C. Watts

P.147 Central Nervous System

(CNS) complications of multiple

myeloma (MM): Myelomatous

meningitis after allogenic stem cell

transplantation (ASCT)

L. Bujor, M. I. Antunes

P.149 Irradiated tumor volume

influences local control and

progression-free survival in

patients with one to three brain

metastases treated by

radiosurgery

H. L. van der Weide, S. L. de

Kunder, R. M. A. Houben,

G. Bosmans, P. Lambin,

B. G. Baumert

P.129 Feasibility and tolerability of

intraventricular therapy with

alternating etoposide and

liposomal cytarabine: experience

in 33 children with malignant brain

tumors

M. Heinrich, B. Reismüller,

E. Minichmayr, A. Peyrl, I. Slavc

P.140 Ependymomas of the filum

terminale: single institution

experience

F. Van Calenbergh, J. Menten,

J. van Loon, C. Plets, M. Didgar,

J. Goffin

P.141 Spinal cord compression

from neurofibromas in

Neurofibromatosis type 1 patients

J. M. De Campos, M. E. Kusak,

J. F. Fabregat, D. T. Aguirre,

A. Alonso, J. L. Sarasa

P.134 Cranial base meningiomas:

The essential role of stereotactic

radiosurgery

M. E. Kusak, N. E. Martinez Moreno,

J. Gutiérrez Sárraga, G. Rey

Portolés, R. Martínez Álvarez

P.159 Lymphomatosis cerebri (LC)

presenting with orthostatic

hypotension, anorexia, and

paraperesis

A. Keswani, E. Bigio, S. A. Grimm

P.160 Prognostic value of serum

soluble interleukin-2 receptor in

primary central nervous system

lymphoma

M. Okada, M. Kouchi, D. Ogawa,

S. Okubo, K. Miyake, N. Kawai,

T. Tamiya

Coffee Break / Poster viewing / Exhibition

P.004 Reversal of effect of U87

derived micro-vesicles on

biological processes of

glioblastoma multiforme

M. L. Broekman, N. S. L. N. Maas,

J. Skog, X. O. Breakefield, M. Sena

Esteves

P.005 Targeting the relapseinducing

cell population of

glioblastoma

M. Glas, B. Rath, M. Simon,

R. Reinartz, A. Schramme,

D. Trageser, R. Eisenreich,

A. Leinhaas, M. Keller,

H. Schildhaus, S. Garbe,

B. Steinfarz, T. Pietsch,

D. A. Steindler, J. Schramm,

O. Brüstle, U. Herrlinger,

B. Scheffler

P.006 Carbon ion irradiation with

or without the addition of

cilengitide is an effective inhibitor

of integrine-mediated tumor cell

migration

S. Rieken, D. Habermehl,

L. Würth, A. Mohr, K. Lindel,

K. Weber, T. Haberer, J. Debus,

S. E. Combs

P.041 Stromal Derived Factor 1a

(SDF-1a), a homing factor for

mesenchymal progenitor cells, is

elevated in tumor tissue and

plasma of glioma patients

M. Timmer, H. Theiss,

K. Juerchott, C. Ries, I. Paron,

W. Franz, J. Selbig, K. Guo,

J. Tonn, C. Schichor

P.042 Cytoplasmic sublocalization

of the stem cell-associated protein

ASPM is an independent prognostic

factor in astrocytic gliomas

C. Dictus, B. Campos, F. Centner,

J. Bermejo, R. Ahmadi,

A. Unterberg, C. Herold-Mende

P.043 Epo and EpoR in human

glioblastoma – friend or foe?

J. Brunotte, H. C. Bock, W. Brück,

B. Hemmerlein, H. M. Strik

P.007 IGF/IGFBP signalling in

merlin deficient tumours

C. O. Hanemann, S. Ammoun,

M. C. Schmid, N. Ristic,

E. Ercolano, L. Zhou

Room Brussels

Presentation Selected Posters

Session: Quality of life

Chair: J. Heimans (The

Netherlands), W. Grisold (Austria)

P.156 Classification of headache in

patients with malignant gliomas

according to the International

Headache Society (IHS) criteria

K. Woznica, V. Nussgruber,

W. Grisold, S. Oberndorfer

P.020 Supporting patients with a

diagnosis of malignant glioma: the

role of the Neuro-oncology nurse

specialist

M. Stauss, J. Mckee, V. McGowan,

G. Hendry, P. Kane

P.021 Health-related quality of life

in patients with brain tumors

treated with two different type of

fractionation

D. R. Cernea, I. Hosu, T. Flonta,

N. Todor, V. Bogdan

P.022 Preliminary validation of the

EORTC Chemotherapy-Induced

Peripheral Neuropathy Quality of

Life Questionnaire (QLQ-CIPN20)

Spanish version in a series of

multiple myeloma patients treated

with bortezomib

R. Velasco, T. J. Postma,

N. Aaronson, M. Simó, J. Bruna

P.023 Cognition and quality of life

in patients with brain tumors

A. Casarotti, L. Bello, A. Comi,

E. Fava, C. Papagno

P.157 Intravenous and oral

levetiracetam in patients with a

suspected primary brain tumor

and symptomatic epilepsy

undergoing neurosurgery: The

HELLO-Study

O. Bähr, M. Hermisson, S. Rona,

J. Rieger, P. Körtvelyessy,

K. Franz, M. Tatagiba, V. Seifert,

M. Weller, J. P. Steinbach

P.024 The late toxicity of adult

medulloblastoma treatments: the

experience of 4 french centres

M. Sierra Del Rio, H. Brissart,

E. Le Rhun, C. Kerr, D. Delgadillo,

L. Bauchet, M. Blonski,

P. Beauchesne, M. Fabbro,

L. Taillandier

P.025 Characteristics of

spontaneous speech in patients

with low grade gliomas in eloquent

areas before surgery

D. D. Satoer, J. Vork, A. J. P. E.

Vincent, C. M. F. Dirven,

E. G. Visch-Brink

P.016 ‘On-call’ referral patterns of

patients with brain tumours in two

neurosurgical centres: Using data

to organise services

N. Mukerji, J. E. Crossman,

J. Lewis, P. J. Kane

20 www.eano.eu


SCIENTIFIC PROGRAMME

Time

16.30-

17.30

Time

17.30-

18.00

Time

18.00-

19.00

18.00

18.05

18.20

18.35

18.50

Auditorium 1

Keynote Lecture

Chair: G. Perilongo (Italy)

Germ cell tumours – biology and treatment in children and adolescents, M. L. Garre

(Genova, Italy)

Room Brussels

EANO General Assembly

Auditorium 2

Satellite Symposium F. Hoffmann-La Roche Ltd.:

Future treatment approaches in glioblastoma

(Refreshments will be served from 17.30)

Welcome and introduction

James J Vredenburgh (USA)

Therapy for glioblastoma: where are we and where are we going?

Martin van den Bent (NL)

Patterns of progression in glioblastoma

Wolfgang Wick (Germany)

Considering patient needs in glioblastoma: a case study

All

Closing remarks

James J Vredenburgh (USA)

Saturday, September 18, 2010, 20.00 – 24.00

EANO IX PARTY Kruisheren Hotel Maastricht

(Admission 19.45h)

EANO IX Party Contribution per ticket

Regular participants € 80.– per person

PhD students, residents, nurses, trainees € 40.– per person

(only applicable with adequate fee)

Please note that seats are limited and advance registration is mandatory in order to receive a

ticket!

Limited Attendance!

Detailed information please find on page 27.

www.eano.eu 21

SATURDAY, SEPTEMBER 18


SUNDAY, SEPTEMBER 19

SCIENTIFIC PROGRAMME

Time

08.30-

10.00

10.00-

11.00

11.00-

11.30

Time

11.30-

12.00

12.00-

13.00

13.00

Room Copenhagen

Symposium on Neuro-Oncology in Eastern European and Northern African Countries

Chair: R. Soffietti (Torino, Italy), A. Twijnstra (Maastricht, Netherlands)

Neuro-Oncology: an interdisciplinary field in Europe, W. Grisold, (Vienna, Austria)

Neuro-Oncology teaching curriculum, R. Grant (Edinburgh, UK)

Neuro-Oncology across countries:

G. Kaloshi (Albania)

A. Kapreylan (Bulgaria)

M. Kase (Estonia)

P. Molnar (Hungary)

U. Abacioglu (Turkey)

R. Gouider (North Africa and Maghreb)

Round table discussion: Impressions of the situation?

What can be done ? How can the EANO help?

Conclusions: F. Graus (Barcelona, Spain)

Plenary Session:

Advances in surgery and radiotherapy

Chair: B. Baumert (Maastricht, Netherlands), C. Carapella (Rome, Italy)

Surgery in low-grade gliomas: Neurosurgical safe maximal resection, H. Duffau

(Montpellier, France)

Improvement in Stereotactic Radiotherapy, M. Werner-Wasik (Philadelphia, PA, USA)

Coffee Break / Poster viewing / Exhibition

Auditorium 2

EORTC Clinical Trials Update, W. Wick (Heidelberg, Germany)

Chair: R. Grant (Edinburgh, UK)

Keynote Lecture:

Chair: R. Grant (Edinburgh, UK)

Imaging PET and MR, early treatment response, S. Sunaert (Leuven, Belgium)

Communication Awards & Closing Remarks

22 www.eano.eu


M E E T I N G S

Meetings

As per date of printing.

Saturday, September 18, 2010

09.00–11.00 CI-Perinoms Study Meeting Room Copenhagen

14.15–16.15 End-of-Life Study Room Copenhagen

17.00–19.00 LGG Meeting Room Copenhagen

17.30–18.00 EANO General Assembly Room Brussels

Corporate Satellite Symposia – open to all participants

Thursday, September 16, 2010

18.00–19.00 Satellite Symposium Merck Serono Room Auditorium 2

INTEGRIN INHIBITION WITH CILENGITIDE – A CUTTING-EDGE CONCEPT IN GLIOBLASTOMA

Chairs: M. van den Bent, M. Weller

Refreshments will be served from 17.30.

18.00–18.05 Welcome and Introduction M. Weller

18.05–18.20 Current treatment concepts in glioblastoma M. van den Bent

18.20–18.35 Radiotherapy and Integrin inhibition E. Moyale

18.35–18.50 Ongoing clinical trials and the role of the MGMT assay M. Weller

18.50–19.00 Discussion and closing remarks M. van den Bent

Friday, September 17, 2010

18.00–19.30 Satellite Symposium MSD ONCOLOGY Room Auditorium 2

PERSPECTIVES ON GBM: THE CHALLENGES OF TREATING MALIGNANT GLIOMAS

Chair: Martin van den Bent

Perspectives on the Treatment of Elderly Patients with GBM

The Nordic Trial

Annika Malmstrom, MD, Unit of Advanced Palliative Home Care, Linköping University Hospital,

Sweden

The NOA 8 Trial

Wolfgang Wick, MD, Department of Neuro-oncology, University of Heidelberg, Germany

Management of Elderly GBM Patients in 2010

Roy Rampling, MD, Division of Cancer Sciences and Molecular Pathology, University of

Glasgow, Scotland

Perspectives on the Treatment of Grade III Tumors

Management of Grade III Tumors After NOA 4

Martin van den Bent, MD, Rotterdam Cancer Center, Erasmus University Hospital, The

Netherlands

Saturday, September 18, 2010

18.00–19.00 Satellite Symposium F.Hoffmann-La Roche Room Auditorium 2

Refreshments will be served from 17.30.

PROGRAMME:

18.00–18.05 Welcome and introduction James J Vredenburgh (USA)

18.05–18.20 Therapy for glioblastoma:

where are we and where are we going? Martin van den Bent (NL)

18.20–18.35 Patterns of progression in glioblastoma Wolfgang Wick (Germany)

18.35–18.50 Considering patient needs in glioblastoma: a case study All

18.50–19.00 Closing remarks James J Vredenburgh

www.eano.eu 23

MEETINGS - SATELLITES


SCIENTIFIC INFORMATION

SCIENTIFIC INFORMATION

POSTER TOPICS

P01 Cell biology and signalling ............................................................................P001–015

P02 Epidemiology..............................................................................................P016–019

P03 Quality of life..............................................................................................P020–032

P04 Immunology and immunotherapy..................................................................P033–037

P05 In vitro / in vivo models...............................................................................P038–039

P06 Predictive biomolecular markers....................................................................P040–054

P07 New drug delivery methods.................................................................................P055

P08 Neuroimaging of brain tumours.....................................................................P056–068

P09 Glioblastoma multiforme and Anaplastic gliomas (I) + (II)................................P069–123

P10 Low grade gliomas ......................................................................................P124–128

P11 Pediatric brain tumours................................................................................P129–133

P12 Meningiomas..............................................................................................P134–139

P13 Spinal cord tumours ....................................................................................P140–145

P14 Brain and leptomeningeal metastases............................................................P146–150

P15 Neurotoxicity and neuroprotection.................................................................P151–152

P16 Paraneoplastic neurological syndromes ..........................................................P153–155

P17 Supportive and palliative care.......................................................................P156–158

P18 Primary central nervous system lymphoma (PCNSL) ........................................P159–160

P19 New developments in surgery..............................................................................P161

P20 New developments in radiotherapy................................................................P162–165

P21 Miscellaneous .............................................................................................P166–180

24 www.eano.eu


SCIENTIFIC INFORMATION

Publication

Please note that your work will be published in the September issue of Neuro-Oncology.

Programme Changes

The organisers cannot assume any liability for changes in the programme due to external or

unforeseen circumstances.

ORAL PRESENTERS

Slide Preview

It is essential that you load and view your presentation in the preview centre preferably

6 hours before your talk, but not later than 2 hours in advance.

The preview centre is situated on level 1 in Office Room 1.3

Speaking Time

The chairpersons of your session will be strict in allowing no more than the time allotted to

your paper. Remember to allow some time for the changeover of speakers and chairperson’s

introduction, and for questions and discussion.

Please rehearse your talk to make sure it will fit comfortably into the timeslot available.

Make yourself known to the chairpersons and/or the room assistant in your session room

before the beginning of the session.

Projection and Technical Setting

• All rooms will be equipped with data-projection (no slides).

• The lecture rooms are exclusively equipped with Windows-PCs (no Macintosh machines).

Should you absolutely have to use your own laptop or notebook, please contact the

congress office in advance.

• Please bring a USB-stick, CD-ROM or floppy disk all formatted for Windows® (PC). You

may want to carry a second disk/CD as a back-up in case there is any insoluble technical

problem.

• File Format: Microsoft® Power Point presentation formatted for Windows® (PC) only.

(Operating system: Windows XP®)

• Preferred Resolution: XGA (1024 x 768 pixel)

POSTER PRESENTERS

Poster Format

The usable surface on the poster board will be 90 cm width x 130 cm height (approx. 35 x 51

inches) and posters should be in upright format.

Poster Mounting and Removal

You will find your poster board number in the author index at the end of the abstract book.

Mounting will be possible on: Friday, September 17, 2010 from 07.30 to 14.00.

Material for mounting the posters will be available.

Removal will be possible on: Sunday, September 19, 2010 at 11.30 – 13.00.

(Please note that posters not removed until then will be taken down by the congress staff and

will not be stored or sent to the authors after the meeting.)

The organisers cannot assume any liability for loss or damage of posters displayed in the poster

area. Posters that are not removed after the end of the closing ceremony on Sunday, September

19, 2010, 13.00, will be removed by staff and will not be stored or forwarded to the author after

the meeting.

www.eano.eu 25

SCIENTIFIC INFORMATION


SCIENTIFIC INFORMATION

SCIENTIFIC INFORMATION

Presence at Posters

In order to enable discussion and interaction with other participants, we request you or one of

your group to be at your poster board at the time indicated below:

*Friday, September 17, 2010 from 14.30 – 15.30 for the following posters topics:

01. Cell biology and signalling

02. Epidemiology

03. Quality of life

04. Immunology and immunotherapy

05. In vitro / in vivo models

06. Predictive biomolecular markers

07. New drug delivery methods

08. Neuroimaging of brain tumours

09. Glioblastoma multiforme and Anaplastic gliomas (I)

*Saturday, September 18, 2010 from 14.00 – 15.00 for the following posters topics:

09. Glioblastoma multiforme and Anaplastic gliomas (II)

10. Low grade gliomas

11. Pediatric brain tumours

12. Meningiomas

13. Spinal cord tumours

14. Brain and leptomeningeal metastases

15. Neurotoxicity and neuroprotection

16. Paraneoplastic neurological syndromes

17. Supportive and palliative care

18. Primary central nervous system lymphoma (PCNSL)

19. New developments in surgery

20. New developments in radiotherapy

21. Miscellaneous

If this is not possible, please leave a note on your poster board indicating the times when you

will be present.

26 www.eano.eu


SOCIAL EVENTS

Thursday, September 16, 2010, 19.30 – 21.00

Welcome Reception in the Provincial Government Building („Gouvernement aan de Maas“)

You will be served fingerfood and drinks while enjoying the beautiful atmosphere in the Provincial

Government Building of Maastricht.

Dress code: casual smart

Free for registered participants and accompanying persons.

Please note that advance registration is mandatory in order to receive a ticket!

Limited attendance!

ADDRESS: Limburglaan 10, 6229 GA Maastricht

HOW TO GET THERE: by walking 5-10 minutes from MECC – please see the map on the back side

of the invitation or ask at the registration desk.

Saturday, September 18, 2010, 20.00 – 24.00

EANO IX PARTY Kruisheren Hotel Maastricht

(Admission 19.45h)

Kruisheren Hotel Maastricht is situated in the centre of Maastricht is the former Kruisheren

(Crutched Friar) cloister, dating from the fifteenth century. Together with the monumental gothic

church, this complex has been transformed into a very special designer hotel. It is a unique place,

in which antiquity and modern design are interwoven; yet, at the same time, architectural contrasts

between the past and the present are very clear.

The interior has been created by the internationally renowned interior designer Henk Vos. The

basic principles are transparency, space, modernity and comfort. Throughout the complex, use

has been made of the notable designs of masters such as Le Corbusier and Rietveld as well as

modern designers like Marc Newson, Piet Heyn Eeck, Philippe Starck and Roderick Vos. These designs

form exciting contrasts with the stained glass windows and the stunning, authentic wall and

ceiling paintings. Surrounded by peaceful cloister corridors, the garden has also been restored

to its former glory: a haven of peace amid the hustle and bustle of the city. Beautiful pieces of

light installation artwork created by the German light installation artist Ingo Maurer provide the

finishing touch to the interior and exterior of the building. The result is challenging, but at the

same time it is a tribute to contemporary architecture and age-old architecture and construction:

a complementary contrast between past and present.

EANO IX Party Contribution € 80.– per person for regular participants

for PhD students, residents, nurses, trainees € 40.– per person

(only applicable with adequate fee)

Dress code: casual smart

Please note that seats are limited and advance registration is mandatory in order to receive a

ticket!

Limited Attendance!

ADDRESS: Kruisherenhotel Maastricht, Kruisherengang 19-23, 6211 NW Maastricht

HOW TO GET THERE

Public transport from MECC: Bus No. 3, get off at ‘Papenstraat’. Next to Vrijthof square walk

slightly uphill into Tweebergarstraat, take first street on your left. OR Bus No. 8, get off at

‘Boschstraat/Markt’. On the market square follow the Grotegracht uphill and turn into the first

street on your left. OR any Bus lines (to Market Place): and walking 5 to 7 minutes

Car parks: € 7.50 for 3 hours – Please pay at the registration desk.

www.eano.eu 27

S O C I A L E V E N T S


GENERAL INFORMATION

GENERAL INFORMATION

Badges

Participants should collect name badges from the conference registration desks. Since only

registered participants will be permitted to attend the scientific sessions, the exhibition and poster

areas, you are kindly asked to wear your badge when entering the congress venue.

Accompanying persons and exhibitors will also receive badges to allow access to the respective

areas.

Lost badges can be replaced at the registration desk. However, a handling fee of EURO 30.- will

be charged.

Bank services – Money matters

Bank opening hours vary per office.

There are multiple bank machines open 24 hours a day throughout the city (also at MECC) which

accept all major international bankcards. The official currency of the Netherlands is the Euro (€).

Major credit cards are widely accepted, but please always check beforehand.

Cancellations and Refunds

Notice of cancellation must be made in writing, by registered letter or fax to the congress office.

Registration fees will be refunded as follows:

Written cancellation received:

- by 31 July 2010: 75% refund

- after 31 July 2010: no refund

The date of the postmark or fax ID will be considered for refund policy. Please indicate your

preferred method of reimbursement (cheque or bank transfer, incl. account number) on your

written cancellation. All refunds will be made after the congress.

Car Parking

Participants may park their car in the parking lot P4, P6 at MECC.

Costs: € 9.50/day.

Certificate of Attendance

Confirmations of attendance will be issued at the registration desk.

Climate

The temperature in September is around 20 degrees celsius (68 degrees Fahrenheit) average.

Evenings are cooler and light jackets or sweaters are recommended.

Cloakroom and Luggage

A cloakroom and luggage storage facilities are available in the congress venue on Level 0.

Please note that the cloakroom will be staffed only Sunday from 08.00 – 13.30.

CME credits

The EANO has applied for credits at the European Accreditation Council for

Continuing Medical Education, Institution of the UEMS. The number of

credits will figure on the respective confirmation, which will be sent after

the meeting.

The rules of the EACCME state that participants are kindly asked to fill in

the feedback form included in the conference bag. It can be returned to

the registration desk.

Participants applying for credits will have to have their badge scanned daily at the CME desk in

the registration area before entering the conference.

Coffee Breaks

Refreshments (coffee, tea, and water) will be served free of charge to participants wearing name

badges during the congress hours.

28 www.eano.eu


GENERAL INFORMATION

Congress venue

MECC

Forum 100, PO Box 1630, 6201 BP, Maastricht, The Netherlands

Currency

The official currency of The Netherlands is the Euro (€). 1 EUR = 1.27 USD = 0.82 GBP = 108

JPY = 1.31 CHF as per date of printing.

Drinking water

Tap water in Maastricht is purified so it is suitable for drinking. Most people, however, prefer to

drink bottled water because it tastes better and is moderately priced. Please find water stations

within the congress area at the MECC.

Eating Out in Maastricht

Lunch is normally served from 13.00 to 15.00 hrs, and dinner between 19.00 and 21.30 hrs.

Electricity Supply

220V - 50Hz AC. Adaptors can be obtained from your hotel reception or electronics stores.

Exhibition Opening Hours

Thursday, September 16, 2010 09.00 – 17.00 hrs

Friday, September 17, 2010 08.00 – 18.00 hrs

Saturday, September 18, 2010 08.00 – 18.00 hrs

Sunday, September 19, 2010 08.00 – 13.00 hrs

GSM cell phone roaming

GSM cell/mobile phone roaming is available without any problems for all major international

providers. It is advisable to ask your provider beforehand which roaming company in The

Netherlands offers the cheapest tariffs.

Insurance

By registering for the EANO 2010 participants agree that neither the organising committee nor

the congress office assume any liability whatsoever. Participants are requested to make their

own arrangements for health and travel insurance.

Internet

Internet stations – sponsored by F. Hoffmann-La Roche Ltd. – are provided to EANO delegates

in the poster area on level 1 as well as in the MECC Cafe – please follow the signage or ask at

the registration desk. WIFI access will be available within the registration area on level 1. You

may also find small internet cafés throughout the city.

Language

The official language of the congress is English (no simultaneous translation).

Lunch and Refreshments

Lunch tickets for lunches on Thursday (Educational Day), Friday and Saturday are included in the

registration fee but had to be pre-ordered on the registration form – they cannot be purchased

on site.

Maastricht

Maastricht is one of the oldest cities in the Netherlands – a city that has ripened well with age,

like good wine, with complex and lively cultural overtones added over centuries by the Romans,

Germans and French. This rich cultural palette is the secret behind the city’s attractiveness,

drawing visitors to the historic city centre and a wealth of museums and festivals – making each

visit a fascinating new experience.

www.eano.eu 29

GENERAL INFORMATION


GENERAL INFORMATION

GENERAL INFORMATION

But Maastricht is also a vibrant and contemporary city with a rich landscape of upmarket as well

as funky boutiques and a wide range of restaurants & cafés serving everything from local dishes,

hearty pub food, and great selections of beer to the very best haute cuisine. And of course its

location also makes Maastricht special – in the heart of the South Limburg hill country and nestled

in the Meuse River Valley.

Medical care

The Dutch National Health Service may be used by all persons from European Union countries who

have the EHICard. This form should be obtained at the health service or post office of the visitor’s

home country before travelling to the Netherlands. It is advisable for participants from countries

outside the European Union to take out medical insurance before reaching the Netherlands since

they will be charged for access to the national health system.

Message Board

A Message Board is available in the Registration Area.

Pharmacies

Medicines that do not require a medical prescription may be purchased directly over the counter.

If you need advice, do not hesitate to ask the pharmacist. If you usually take medication, it is

advisable to bring a sufficient amount with you for your trip. There are duty pharmacies open

24 hours a day in most city districts.

Poster Removal – see Scientific Information

Preview Room

Equipment for a final check of the sequence of your presentation is available in the preview room.

All presenters should bring their electronic presentation to the preview room preferably in the

morning of the day of the talk, but no later than 2 hours before the start of the session.

Public Transport

Your EANO 2010 name badge will be a valid public transportation ticket for Maastricht area. This

will be valid under the condition that you carry your name badge with you while in the public

transport. Your name badge will work as a public transport ticket from September 16 to

September 19, 2010.

Registration Desk opening hours

Thursday, September 16, 2010 08.30 – 19.00 hrs

Friday, September 17, 2010 07.00 – 19.30 hrs

Saturday, September 18, 2010 07.30 – 19.00 hrs

Sunday, September 19, 2010 08.00 – 13.30 hrs

Safety – Crime

Visitor safety is generally adequate. As in any other European city, you can walk everywhere

using common sense.

Unfortunately experience has shown that some basic precautionary measures should always be

kept in mind in any city:

• Do not carry important items like flight tickets, passports etc. with you when visiting the

conference or strolling through the city. Leave them in the hotel safe during your stay. Rather,

carry a photocopy of your passport or an identity card with you.

• Try not to carry all documents, money, credit cards and other essential items and valuables in

one bag. If it gets lost or stolen, everything will be gone and might be difficult to replace on

short notice, especially passports and visa to return to your country of residence.

30 www.eano.eu


GENERAL INFORMATION

Shops

Shops in Maastricht are open

Monday 13.00 – 18.00

Tuesday and Wednesday 09.00 – 18.00

Thursday 09.00 – 21.00

Friday 09.00 – 18.00

Saturday 09.00 – 17.00

Smoking Policy

The EANO 2010 is a “No-smoking-Conference” and MECC is a no-smoking-building.

Please note that smoking is banned from all public buildings, restaurants and bars

Staff

Should you have any questions, congress staff will be pleased to help you. Please contact the

registration desk.

Taxis

Taxis can be identified by their sign on the roof.

Technical Exhibition Organiser

Medizinische Ausstellungs- und Werbegesellschaft (MAW)

Ms. Andrea Etz

Freyung 6, A-1010 Vienna, Austria

T : +43 1 536 63-42, M: +43/664/46 30 448

F : +43 1 535 60 16

maw@media.co.at

Tipping

Tips are not obligatory in the Netherlands, although people usually leave them at restaurants

(a maximum of 10% of the total amount of the bill). Hotel and airport porters will accept tips,

depending on the luggage.

Travelling – Accessibility

Maastricht can easily be reached by train or bus. The main station is centrally located, and most

of the city’s attractions are within walking distance.

For EANO participants transportation by citybuses is for free. For this service the conference

badge needs to be shown to the bus driver.

Travelling to the congress venue by public transportation

Take the buss to MECC/ AZM Medical Centre. Lines 1, 3 and 10 go directly to the MECC

From the airport:

Maastricht-Aachen Airport is located not far from the city centre, and the airports of Brussels,

Weeze-Niederrhein (Dusseldorf North), Köln-Bonn and Eindhoven are located about 60-90

minutes away by car.

Transportation from Brussels or Dusseldorf to Maastricht can be ordered in advance through

www.maastrichtbookingservice.nl

V.A.T.

A value-added tax (V.A.T.) of 6% (food) to 19% (other items) is applied to all products and

services. In most cases it is included in the price. Whenever it is not included, however, it will be

clearly specified.

www.eano.eu 31

GENERAL INFORMATION


REGISTRATION FEES

REGISTRATION FEES

Onsite registration is possible at the following Registration Opening Hours:

Thursday, September 16, 2010 08.30 – 19.00 hrs

Friday, September 17, 2010 07.00 – 19.30 hrs

Saturday, September 18, 2010 07.30 – 19.10 hrs

Sunday, September 19, 2010 08.30 – 13.30 hrs

Payment received by 15 June 25 August after 25 August 2010

2010 2010 and on site

Regular participants/members EUR 350.– EUR 400.– EUR 470.–

Regular participants/non members EUR 550.– EUR 620.– EUR 670.–

PhD students and residents1 EUR 200.– EUR 200.– EUR 200.–

Nurses, Trainees2 EUR 150.– EUR 150.– EUR 200.–

Accompanying persons EUR 40.– EUR 60.– EUR 60.–

1 ) Please provide a copy of a Student's ID or a confirmation signed by the head of department at the moment of your

registration

2 ) applies to trainees only if younger than 35 years, please provide a copy of an ID together with your registration.

For the EANO IX Educational course 16 September 2010

Registration fee: EUR 150.– Includes: admission to courses of your choice, syllabus, coffee breaks

and lunch box for 1 day (Thursday)

What is covered by the registration fee?

Participants: Admission to all scientific sessions, exhibition and welcome reception, Abstract book

and Programme, Coffee breaks, Lunch boxes on 2 days (Friday and Saturday), public

transportation ticket.

Accompanying persons: Admission to the welcome reception (No admission to lectures)

IMPORTANT: The reduced registration fee is only applicable, if it has been credited to the congress

account before the respective deadline. Registering before the deadline without performing an

actual payment is not sufficient to benefit from the reduction. Please note that a different fee

applies for on-site registrations.

If the fee is not transferred to the congress bank account before the deadline the fee will

automatically change to the higher fee.

Payment of registration fees:

to be made in advance in EURO by:

• Bank transfer to bank account "EANO 2010" No. 286 274 963 58, Bank/Routing code 20111,

SWIFT/BIC: GIBAATWW, at the Erste Bank, Alser Strasse 23, 1080 Vienna, Austria, IBAN

AT93 20111 28627496358 – to avoid bank charges; please use the IBAN within the EU.

Payments to be made free of charge to the beneficiary. Any bank charges will be collected on

site. Clearly state the participant's name(s), as indicated on the registration form.

• Cheque. Bank cheques free of charge to the beneficiary, must be payable to "EANO 2010" c/o

Vienna Medical Academy, Alser Strasse 4, A-1090 Vienna, Austria.

Cancellations and refunds

Notice of cancellation must be made in writing, by registered letter or fax, to the Conference

Secretariat:

Registration fees will be refunded as follows:

Written cancellation received: - by 31 July 2010: 75% refund

- after 31 July 2010: no refund

The date of the postmark or fax ID will be considered for refund policy. Please indicate your

preferred method of reimbursement (cheque or bank transfer, incl. account number) on your

written cancellation. All refunds will be made after the congress.

32 www.eano.eu


NOTES

www.eano.eu 33

NOTES


EXHIBITORS STANDING

EXHIBITORS STANDING

Trajectum

14

Catering

8

postersession

8

Internet

1

2

3

=scale

4 5 6

Catering

Auditorium 2

As per date of printing

34 www.eano.eu

7

Catering

Catering

8

Catering

12

11

10

9

MECC Cafe:

Internet stations

(sponsored by

F. Hoffmann-

La Roche Ltd.)


EXHIBITORS LISTING

The European Association of NeuroOncology gratefully acknowledges the support of the

following institutions, companies and organisations (list correct as per date of printing):

in Alphabetical Order

1 Internet stations (sponsored by F. Hoffmann-La Roche Ltd.)

2 STOPhersentumoren.nl (foundation for primary braintumor research),

Driebergen, The Netherlands

3 Deutsche Hirntumorhilfe e.V., Leipzig, Germany

4 IBTA (International Brain Tumour Alliance), Tadworth, United Kingdom

5 Oxford University Press, Oxford, United Kingdom

6 MSD Oncology, Whitehouse Station, United States

7 Merck Serono, Darmstadt, Germany

8 EANO – (European Association of NeuroOncology), Kaatsheuvel, The Netherlands

9 Wisepress, London, United Kingdom

10 Mundipharma Pharmaceuticals, Hoevelaken, The Netherlands

11 OncoMethylome Sciences, Heverlee, Belgium

12 Novocure, Haifa, Israel

www.eano.eu 35

EXHIBITORS LISTING


MAP PUBLIC TRANSPORTATION MAASTRICHT


MAP PUBLIC TRANSPORTATION MAASTRICHT





















































































































36 www.eano.eu


The EUROPEAN

ASSOCIATION of

NEUROONCOLOGY

10th MEETING

See See you!

you!

September 6-9

MARSEILLE

PARC CHANOT Convention & Exhibition Centre FRANCE

www.eano.eu

2012


PLEASE JOIN US!

PERSPECTIVES ON GBM: THE CHALLENGES

OF TREATING MALIGNANT GLIOMAS

AN MSD ONCOLOGY SATELLITE SYMPOSIUM

AT THE 9TH EANO CONGRESS

FRIDAY, 17 SEPTEMBER 2010 18:00 – 19:30

AUDITORIUM 2 MAASTRICHT EXHIBITION & CONGRESS CENTRE

SYMPOSIUM AGENDA:

Perspectives on the Treatment

of Elderly Patients with GBM

The Nordic Trial

Annika Malmstrom, MD

Unit of Advanced Palliative Home Care

Linköping University Hospital, Sweden

The NOA 8 Trial

Wolfgang Wick, MD

Department of Neuro-oncology

University of Heidelberg, Germany

Management of Elderly GBM

Patients in 2010

Roy Rampling, MD

Division of Cancer Sciences and Molecular Pathology

University of Glasgow, Scotland

Perspectives on the Treatment of

Grade III Tumors

Management of Grade III Tumors

After NOA 4

Martin van den Bent, MD

Rotterdam Cancer Center

Erasmus University Hospital, The Netherlands

Program Chair:

Martin van den Bent, MD

Rotterdam Cancer Center

Erasmus University Hospital

The Netherlands

More magazines by this user
Similar magazines